GPR40 Activation Abolishes Diabetes-Induced Painful Neuropathy by Suppressing VEGF-A Expression
Authors:
Open Access
- 21 January 2022
- journal article
- research article
- Published by American Diabetes Association in Diabetes
- Vol. 71 (4) , 774-787
Abstract
G-protein–coupled receptor 40 (GPR40) is a promising target to support glucose-induced insulin release in patients with type 2 diabetes. We studied the role of GPR40 in the regulation of blood-nerve barrier integrity and its involvement in diabetes-induced neuropathies. Because GPR40 modulates insulin release, we used the streptozotocin model for type 1 diabetes, in which GPR40 functions can be investigated independently of its effects on insulin release. Diabetic wild-type mice exhibited increased vascular endothelial permeability and showed epineural microlesions in sciatic nerves, which were also observed in naïve GPR40−/− mice. Fittingly, expression of vascular endothelial growth factor-A (VEGF-A), an inducer of vascular permeability, was increased in diabetic wild-type and naïve GPR40−/− mice. GPR40 antagonists increased VEGF-A expression in murine and human endothelial cells as well as permeability of transendothelial barriers. In contrast, GPR40 agonists suppressed VEGF-A release and mRNA expression. The VEGF receptor inhibitor axitinib prevented diabetes-induced hypersensitivities and reduced endothelial and epineural permeability. Importantly, the GPR40 agonist GW9508 reverted established diabetes-induced hypersensitivity, an effect that was blocked by VEGF-A administration. Thus, GPR40 activation suppresses VEGF-A expression, thereby reducing diabetes-induced blood-nerve barrier permeability and reverting diabetes-induced hypersensitivities.Keywords
All Related Versions
This publication has 50 references indexed in Scilit:
- Altered C-Fiber Function as an Indicator of Early Peripheral Neuropathy in Individuals With Impaired Glucose ToleranceDiabetes Care, 2010
- Advanced Glycation End Products in Extracellular Matrix Proteins Contribute to the Failure of Sensory Nerve Regeneration in DiabetesDiabetes, 2009
- GPR40: Good Cop, Bad Cop?Diabetes, 2009
- Axitinib for renal cell carcinomaExpert Opinion on Investigational Drugs, 2008
- Glucose neurotoxicityNature Reviews Neuroscience, 2008
- Neurotrophic modulation of myelinated cutaneous innervation and mechanical sensory loss in diabetic miceNeuroscience, 2007
- Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small moleculesBritish Journal of Pharmacology, 2006
- The pathogenesis of diabetic retinopathy: old concepts and new questionsEye, 2002
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- Angiotensin II Increases Vascular Permeability Factor Gene Expression by Human Vascular Smooth Muscle CellsHypertension, 1995